October 20, 2022
Life Sciences
  • The Food and Drug Administration (FDA) authorized a booster dose of Novavax’s COVID-19 vaccine. The booster was authorized for adults ages 18 and older who can’t take an mRNA vaccine or don’t have access to one, as well as for adults who would otherwise not receive a booster. The Centers for Disease Control and Prevention (CDC) subsequently recommended its use. Unlike the bivalent mRNA vaccines, Novavax’s booster is not an omicron-specific vaccine – it only targets the original strain of the virus. (Press release here; Articles here, here, here, here, here, and here)